Dashboard
Manage Tickers

ALDX Aldeyra Therapeutics, Inc.

Nasdaq aldeyra.com


$ 5.43 $ 0.18 (3.42 %)    

Monday, 20-Oct-2025 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 5.44
$ 5.34
$ 5.44 x 200
$ 5.51 x 20
$ 5.26 - $ 5.46
$ 1.14 - $ 7.20
585,050
na
325.83M
$ 1.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 10-28-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 03-08-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-29-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-30-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-10-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

4-biotechnology-stocks-lead-momentum-gains-amid-strong-technicals
4 Biotechnology Stocks Lead Momentum Gains...
10/10/2025 08:32:04

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.

4-biotech-stocks-seeing-explosive-momentum-gains
4 Biotech Stocks Seeing Explosive Momentum...
10/07/2025 15:19:18

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here...

aldeyra-wins-ema-orphan-drug-status-for-adx-2191-to-treat-rare-eye-cancer
Aldeyra Wins EMA Orphan Drug Status for AD...
08/28/2025 11:22:38

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan ...

aldeyra-therapeutics-says-fda-grants-fast-track-designation-for-adx-2191-for-treatment-of-retinitis-pigmentosa
Aldeyra Therapeutics Says FDA Grants Fast ...
08/19/2025 11:05:25

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted...

aldeyra-therapeutics-receives-orphan-designation-from-european-medicines-agency-for-adx-2191-in-treatment-of-inherited-retinal-dystrophies-including-retinitis-pigmentosa
Aldeyra Therapeutics Receives Orphan Desig...
07/24/2025 11:06:15

aldeyra-therapeutics-announces-fda-acceptance-for-review-the-resubmitted-new-drug-application-for-reproxalap
Aldeyra Therapeutics Announces FDA Accepta...
07/17/2025 11:02:30

aldeyra-therapeutics-receives-fda-special-protocol-assessment-agreement-letter-for-adx-2191-to-treat-primary-vitreoretinal-lymphoma
Aldeyra Therapeutics Receives FDA Special ...
06/26/2025 11:03:02

aldeyra-resubmits-eye-drug-for-fda-review-after-new-trial-clears-key-hurdle-in-treating-dry-eye
Aldeyra Resubmits Eye Drug for FDA Review ...
06/17/2025 11:03:53

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative th...

hc-wainwright--co-reiterates-buy-on-aldeyra-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Alde...
05/19/2025 10:36:45

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
05/06/2025 12:08:25

aldeyra-therapeutics-to-announce-topline-results-from-phase-3-dry-eye-disease-clinical-trials-of-reproxalap-at-conference-call-scheduled-on-may-6-2025
Aldeyra Therapeutics To Announce Topline R...
05/05/2025 20:08:45

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
05/05/2025 17:35:21

btig-maintains-buy-on-aldeyra-therapeutics-lowers-price-target-to-9
BTIG Maintains Buy on Aldeyra Therapeutics...
04/07/2025 15:40:11

BTIG analyst Thomas Shrader maintains Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and lowers the price target from $11 to $9.

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
04/04/2025 17:06:22

hc-wainwright--co-reiterates-buy-on-aldeyra-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Alde...
04/04/2025 10:24:08

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 ...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
04/03/2025 21:05:48

11-health-care-stocks-moving-in-thursdays-intraday-session
11 Health Care Stocks Moving In Thursday's...
04/03/2025 17:06:22

crude-oil-dips-7-ism-services-pmi-falls-in-march
Crude Oil Dips 7%; ISM Services PMI Falls ...
04/03/2025 16:13:08

dow-tumbles-over-1100-points-us-initial-jobless-claims-fall
Dow Tumbles Over 1,100 Points; US Initial ...
04/03/2025 13:42:39

fda-rejects-aldeyras-reproxalap-for-dry-eye-disease-again-citing-efficacy-concerns
FDA Rejects Aldeyra's Reproxalap For Dry E...
04/03/2025 13:37:43

The FDA rejected Aldeyra's resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION